Hepatic safety of caspofungin during treatment of invasive fungal diseases in elderly patients

To the Editor： Caspofungin is a new class of antifungal agents （echinocandins） for the treatment of fungal infections. Bynoncompetitive inhibition β-（1,3）-D-glucan synthase, it can destroy the glucan synthesis of the fungal cell wall and produce bactericidal activity. β-（1,3）-D-glucan does not exist...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2012-06, Vol.125 (12), p.2240-2240
Main Authors: Wang, Li-Li, Zhuge, Xin, Xiao, Guang-Hui, Zhang, Yun
Format: Article
Language:English
Subjects:
Aged, 80 and over
Echinocandins - adverse effects
Echinocandins - therapeutic use
Humans
Lipopeptides
Liver - drug effects
Liver Function Tests
Mycoses - drug therapy
Retrospective Studies
侵袭性
安全
患者
抗真菌药物
治疗
真菌病
老年
肝脏
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To the Editor： Caspofungin is a new class of antifungal agents （echinocandins） for the treatment of fungal infections. Bynoncompetitive inhibition β-（1,3）-D-glucan synthase, it can destroy the glucan synthesis of the fungal cell wall and produce bactericidal activity. β-（1,3）-D-glucan does not exist in mammalian cells; thus the toxicity of this drug could be avoided.1 In a recent meta analysis on tolerance and liver toxicity of antifungal agents, Wang et al2 showed that caspofungin had less side effects and better hepatic safety than the other antifungal agents. The pooled risks of treatment discontinuation due to adverse reactions were above 13.4% for amohotericin B.
ISSN:0366-6999
2542-5641
DOI:10.3760/cma.j.issn.0366-6999.2012.12.030